Juniper Biosciences Raises Oversubscribed and Upsized $40 Million Seed Financing to Fund Development of Its Innovative Pipeline

Financing co-led by NovaCapital, private high-net-worth individuals and members of Club Degli Investitori “We are thrilled to have the support of a diverse investor base who believe strongly in the promise that radiopharmaceuticals offer to the future of patient care.” said Alex Agnoletto, CEO. “Our founding team brings deep expertise within global radiopharmaceutical development and manufacturing and is well positioned to advance our pipeline to address patient needs.” About Juniper...

BRIDGEWATER, 01/12/2025 (informazione.news - comunicati stampa - salute e benessere)

“We are thrilled to have the support of a diverse investor base who believe strongly in the promise that radiopharmaceuticals offer to the future of patient care.” said Alex Agnoletto, CEO. “Our founding team brings deep expertise within global radiopharmaceutical development and manufacturing and is well positioned to advance our pipeline to address patient needs.”

About Juniper Biosciences

Juniper Biosciences is an innovative radiopharmaceutical drug development company led by Alex Agnoletto (CEO), Dr. Indranil Nandi (COO), and Dr. Kyle Hoffmann (Dir. Manufacturing). The Company’s pipeline is currently confidential and contains several assets in various stages of development.

“We’re truly excited about the transformative potential of Juniper Biosciences’ patient-centric product pipeline to drive meaningful progress in radiopharmaceutical imaging and therapy in coming years” said Dr. Indranil Nandi, COO.

Juniper’s leadership team:

Management Team:

Board of Directors :

Please visit www.juniperbiosci.com for more information.

For further information please contact:

Alex Agnoletto, CEO

Alex.Agnoletto@juniperbiosci.com